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Background and purpose   The presence of bone marrow edema 
in patients with osteoarthritis is associated with pain and dis-
ease progression. Management of bone edema with the synthetic 
prostacyclin iloprost may be complicated by side effects. Calcium 
dobesilate, a treatment for chronic venous disease, shares some 
pharmacological actions with iloprost but appears to be better tol-
erated. Anecdotal reports have suggested that calcium dobesilate 
may be useful for medical management of osteoarthritis, possibly 
by reducing bone marrow edema, and this study was performed 
to investigate possible benefits of treatment.
Methods   The effects of a 6-week period of oral calcium dobe-
silate administration on tibial intramedullary pressure dynam-
ics and physical joint characteristics were evaluated in 20 rab-
bits with unilaterally induced knee osteoarthritis that were ran-
domly allocated to either a treatment group or a placebo control 
group. Treatment or placebo started 8 weeks after induction of 
osteoarthritis, and was followed by a 4-week washout period.
Results   Calcium dobesilate did not affect joint thickness or 
range  of  motion,  nor  individual  pressure  measurements,  com-
pared  to  placebo.  Pressure  ranges  in  the  operated  limb  were 
greater than in the intact limb after 8 weeks, and approached 
those of the intact limb after 6 weeks of treatment with calcium 
dobesilate but not with placebo. Inter-limb differences were lower 
(p = 0.02) in the dobesilate group following the washout period.
Interpretation      Calcium  dobesilate  had  a  detectable  effect 
on pressure dynamics in the subchondral bone of osteoarthritic 
joints in this model. The significance of these effects for pain and 
function should be established.

Osteoarthritis  is  a  common  condition  causing  disability  in 
elderly human and veterinary patients (Vaughan 1990, Felson 
and Zhang 1998). The precise cause of pain in osteoarthritis 
is  unknown  (Felson  et  al.  2001).  Intra-articular  anesthe-
sia does not universally produce pain relief in patients with 
osteoarthritis (Creamer et al. 1996), which suggests that extra-
articular sources of pain may be involved.
Patients with knee pain are more likely to have bone marrow 
edema on MRI than those without pain (Felson et al. 2001), 
and presence of bone marrow edema is a risk factor for pro-
gression of knee osteoarthritis (Felson et al. 2003).
The cause of the edema is unclear. Arnoldi et al. (1980) pro-
posed that impaired venous drainage from the bone marrow 
could be a cause of pain in osteoarthritis, and increased intra-
medullary pressures have been reported in the femoral head 
of humans with osteoarthritic hips (Kiaer et al. 1988). Fricker 
et  al.  (1995)  have  proposed  that  accumulation  of  osmoti-
cally active proteins in the subchondral bone tissue leads to 
development of a local compartment syndrome and increased 
intraosseous pressure in osteoarthritis; resorption of these pro-
teins will lead to resolution of the compartment syndrome and 
break the cycle of worsening disease.
Tramadol and the synthetic prostacyclin iloprost have pro-
vided similar analgesia in patients with painful bone marrow 
edema of the knee, but regression of edema was found to be 
more pronounced in the patients receiving iloprost (Mayer-
hoefer et al. 2007). Improvements in symptoms with iloprost 
treatment have also been reported for bone marrow edema of 
the foot (Aigner et al. 2005). The actions of iloprost include 
inhibition of platelet and leukocyte activation, vasodilatation, 
and  reduction  of  vessel  wall  permeability  (Grant  and  Goa 
1992). Reported side effects in man include severe headaches, 
erythema, and nausea (Aigner et al. 2001, Jager et al. 2008).
Calcium dobesilate (calcium 2,5-dihydroxybenzene sulfo-
nate) is a synthetic venoactive drug with multiple effects that 
include inhibition of serotonin-, bradykinin-, and histamine-
induced capillary permeability, inhibition of prostaglandin and 
thromboxane synthesis (resulting in reduced platelet aggrega-
tion and blood viscosity), reduction of experimental lymph-
edema and intralymphatic pressure, increased lymphatic flow, 
reduced angiogenesis, and reduced albumin leakage (Tejerina Acta Orthopaedica 2011; 82 (5): 622–627  623
and Ruiz 1998). Macrophage-driven removal of proteins has 
been described in models of lymphedema (Casley-Smith and 
Casley-Smith 1985). Many of these actions are comparable to 
those of iloprost. Oral safety in animals appears high (Tejerina 
and Ruiz 1998) and in a large study of diabetic patients, no rel-
evant drug-related complications were recorded (Haritoglou 
et al. 2009). Efficacy in reducing lower limb edema has been 
shown in patients with chronic venous disease (Flota-Cervera 
et al. 2008).
Calcium  dobesilate  treatment  of  navicular  syndrome  in 
horses, characterized by increased intramedullary pressures 
and edema in the navicular bone (Svalastoga and Smith 1983, 
Pool  et  al.  1989),  has  been  reported  anecdotally  (Fricker 
2008). The oral formulation and low toxicity of calcium dobe-
silate make it an interesting drug for management of bone 
marrow edema. 
This study was designed to investigate the effect of calcium 
dobesilate treatment on intramedullary pressure in a rabbit 
model of osteoarthritis. 
Material and methods
The trial population consisted of 20 age-matched female New 
Zealand White rabbits, housed in groups of 5 in 4m2 pens with 
deep litter and environmental enrichment. The rabbits were 3 
months old and weighed 2.4 kg (SD 0.1 kg) at the start of the 
trial, and they were individually identifiable by means of ear 
tattoos. Approval for their use in this study was obtained from 
the  Animal  Experiment  Inspectorate  (Dyreforsoegstilsynet, 
Denmark).
Anesthesia was induced using a combination of intravenous 
midazolam, fentanyl, and fluanisone, and maintained with iso-
flurane in oxygen.
Knee joint width was measured using digital calipers with a 
spring-loaded contact plate (ReDog, Västerås, Sweden), ensur-
ing that all measurements were made with the same pressure. 
Maximum extension and flexion angles were obtained using 
a goniometer centered on the stifle joint and aligned with the 
greater trochanter proximally and the lateral malleolus of the 
tibia distally. Proximal thigh muscle bulk was evaluated by 
measuring the circumference of the thigh using a measuring 
tape with a spring-loaded marker (ReDog) to ensure that tape 
tension was identical for each measurement.
Following routine aseptic preparation and using the inser-
tion of the medial collateral ligament as a landmark, a 38-mm 
22-gauge spinal needle was inserted through the cortex of 
each tibia, angled slightly proximally, in order to place the tip 
in the medullary cavity below the tibial plateau (Figure 1). The 
bevel was oriented proximally in all instances. Once placed, 
the needle was connected via a 3-way tap and fluid line to a 
pressure transducer (Gabarith PMSET 1DT-XX; Becton Dick-
inson) which was connected to a monitor. Following connec-
tion, the needle was flushed with a small volume (0.1–0.2 mL) 
of 10 IU/mL heparinized saline to ensure patency. If there was 
resistance to injection or no pulsatile waveform was identified, 
the stylet was replaced and the needle advanced and rotated to 
free it from any obstruction. A resting value for intramedullary 
pressure was obtained once the mean pressure reading had 
stabilized and the needle was flushed with 1 mL of heparin-
ized saline to increase the measured pressure to 200 mmHg or 
greater. Peak pressure after injection and mean pressure 15 s 
after injection—and at 30-s intervals for 10 min after comple-
tion of injection—were recorded. All needle insertions were 
performed by one investigator (AW).
Once  pressure  measurements  were  completed  bilaterally, 
the right cranial (anterior) cruciate ligament was transected 
via a lateral mini-arthrotomy, in order to destabilize the joint. 
All ligaments were intact prior to transaction and no instability 
was noted in the unoperated knees. Wound closure was rou-
tine. All surgeries were performed by one investigator (JM).
Perioperative analgesia was provided by subcutaneous injec-
tion of 0.3 mg/kg meloxicam and of 0.03 mg/kg buprenor-
phine. Postoperatively, meloxicam was administered orally at 
0.3 mg/kg once daily for 10 days, and thereafter at 0.1 mg/kg 
once daily throughout the duration of the study.
All measurements were repeated after 8 weeks, and the rab-
bits randomized to treatment and placebo control groups. The 
investigators were blinded regarding which animals were in 
which groups. Rabbits in the treatment group received cal-
cium dobesilate orally, 25 mg/kg twice daily for 6 weeks, 
whereas those in the placebo group received lactose at a dose 
equivalent to that found in the compounded drug.
Measurements were repeated after 6 weeks. The calcium 
dobesilate  and  lactose  treatments  were  withdrawn.  After 
another 4 weeks, final measurements were taken and the rab-
bits were killed.
Statistics
Statistical testing between groups and stages was performed 
using mixed-model ANOVA with SAS 9.1 software, and a 
Bonferroni correction for multiple comparisons was applied. 
Statistical significance was set at p < 0.05.
Figure 1. Study instrumentation. This schematic diagram shows the 
proximally directed 22-gauge spinal needle placed through the medial 
cortex of the tibia, connected via a 3-way tap to a saline-filled syringe 
for flushing and a pressure transducer. The pressure transducer, line, 
and needle were subject to a constant low rate (3 mL/h) flushing with 
saline to ensure patency.624  Acta Orthopaedica 2011; 82 (5): 622–627
Results
Few complications occurred. 1 rabbit died during induction of 
anesthesia at the start of the study, and was replaced by another 
age-matched rabbit. 2 rabbits in the placebo group developed 
a seroma at the operation site, both of which resolved sponta-
neously within a week. An additional needle had to be placed 
in 3 limbs (2 at the pre-treatment stage and 1 at the post-treat-
ment stage) due to failure to obtain a satisfactory placement 
with the first. All needles were patent on removal. All joints 
were unstable after surgery using the Lachman test.
Pressure data were examined to find the minimum (from 
15 s to 150 s) and maximum (from 180 s to 600 s) pressure 
values, the mean pressure value (from 180 s to 600 s) and the 
baseline pressure value prior to saline injection. The time cut-
off points were selected to avoid inclusion of high readings 
from the initial saline injection in the means and maxima. Dif-
ferences in pressure measurements between intact and oper-
ated limbs within each group were compared. No statistically 
significant differences in the minimum, maximum, mean, or 
baseline  pressure  values  were  observed  between  treatment 
groups at any stage.
Pressure  data  were  normalized  to  the  mean  value  found 
above for each stage of the study (Figure 2). Whilst curve 
characteristics were similar for both groups and both limbs 
at the start of the study, the intact and operated limb curves 
diverged in the first 180 s after saline injection by 8 weeks 
after induction of arthritis (p = 0.01). This divergence became 
less in the treatment group by the end of the treatment period 
and became further reduced during the washout period. As a 
Figure 2. Mean-normalized pressure following saline injection for operated and intact limbs in the treatment and placebo groups at the four mea-
surement stages: at induction of arthritis (A), prior to treatment/placebo (B), following treatment/placebo (C), and after washout period (D). Pres-
sure values were individually normalized to the mean value for the time period 180–600 s to simplify comparisons of pressure changes between 
groups. Although mean pressures for all limbs are initially similar, the operated and intact limbs diverge with the development of arthritis. This 
divergence diminishes markedly following treatment with dobesilate, but barely changes in the placebo group. Error bars represent 1 SD.
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measure of this divergence, pressure ranges were calculated 
between the minimum pressure in the time period 15–150 s 
and the mean pressure in the time period 180–600 s for each 
limb.  Differences  in  this  pressure  range  between  operated 
and intact limbs were calculated for each rabbit by subtrac-
tion of the range figure for the operated limb from that of the 
intact limb (Figure 3). No statistically significant differences 
were  found  in  the  pressure  range  differences  between  the 
treatment and placebo groups for the first three stages of the 
study, but the pressure range difference was significantly dif-
ferent between groups at the end of the study (95% CI: 1.9–22 
mmHg; p = 0.02).
Changes  in  joint  width,  maximum  extension  or  flexion, 
range of motion, and thigh circumference were similar for the 
treatment and placebo groups. Compared to the intact stifle, 
joint width increased statistically significantly, and joint maxi-
mum extension, flexion, and range of motion decreased sig-
nificantly over the study period in the operated stifles of both 
the treatment and placebo groups. A difference was found in 
the thigh circumference difference between intact and oper-
ated limbs between the end of treatment and the end stages 
of the study (95% CI: 0.1–0.9 cm; p = 0.005) in the placebo 
group but not in the treatment group.
No statistically significant differences in body weight or 
change in body weight were found between the treatment and 
placebo groups, but differences were found between all stages 
of the study (p < 0.001). 
Discussion
Section of the cranial (anterior) cruciate ligament in rabbits 
reliably induces osteoarthritic changes by 8 weeks (Yoshioka 
et al. 1996), and a rabbit model has been validated previously 
for evaluation of oral medications (Tiraloche et al. 2005).
Our physical findings are in broad agreement with a previ-
ous study of monoarticular arthritis in rabbits (Pitt and Lewis 
1984), and with clinical findings in dogs (Piermattei et al. 
2006). Changes in joint width and maximal extension and 
flexion angles were not affected by treatment with calcium 
dobesilate. Although we expected to find a general reduction 
in thigh circumference in the operated limb relative to the 
intact limb, this was not confirmed. During the study, we felt 
that the use of the measuring tape was not particularly accu-
rate, due to difficulties retaining the tape at the correct height 
on the limb, obstruction of the tape by fur, and subjectivity in 
positioning.
Previous  investigation  of  intramedullary  pressure  in  the 
rabbit gave a wide range of normal values for the resting pres-
sure (Thomas et al. 1982): similarly, we found wide ranges for 
all single pressure measurements (baseline, mean, minimum, 
maximum), which prevented meaningful comparison of the 
raw data. Intramedullary pressures are linearly related to sys-
temic arterial pressures (Kiaer et al. 1990) and it may be that 
individual responses to the anesthesia regime used contributed 
to this wide variation. Analysis of pressure range (from mini-
mum to mean pressure) yielded interesting results. Initially, 
the pressure range was small but it increased dramatically in 
the intact limbs, and moderately in the operated limbs, by 8 
weeks. The cause of this change is unclear. Possible factors 
include meloxicam treatment, the effect of placing a spinal 
needle through the cortex, altered limb loading as a result of 
osteoarthritis, and growth-related changes. The most plausible 
reasons for the difference in effect size between the intact and 
operated limbs are altered weight bearing or intramedullary 
edema. 
Following the treatment period, the pressure ranges of the 
treated limbs became more similar—which could indicate a 
lessening of intramedullary edema or improved weight shar-
ing between the limbs. In contrast, the difference between 
the  hind  limbs  of  the  placebo  group  was  exacerbated:  the 
osteoarthritis could reasonably be expected to have worsened 
further during this period (Yoshioka et al. 1996). Unexpect-
edly, this trend in the treatment limbs continued during the 
washout period at the end of the study. The placebo limbs also 
showed some improvement. This could be due to periarticular 
thickening achieving stabilization of the knee joint, and thus 
an improvement in limb function. The further improvement in 
the treatment limbs may therefore represent a combination of 
acquired joint stability and improvements due to prior dobe-
silate treatment. Perseverance of the drug is unlikely because 
elimination of calcium dobesilate after oral administration is 
50% at 24 h (Tejerina and Ruiz 1998). Interestingly, in a study 
Figure  3.  Pressure  range  differences  between  intact  and  operated 
limbs  for  the  treatment  and  placebo  groups  throughout  the  study 
period (start: start of study; pre: pre-treatment; post: post-treatment; 
end: end of study). The pressure range was defined as the difference 
in measured pressure between the minimum over 15–150 s post-injec-
tion and the mean over 180–600 s post-injection. Differences were cal-
culated as intact range minus operated range and displayed as mean 
values. Error bars represent 1 SD and are shown on one side only for 
clarity.
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of chronic venous disease in humans it was noted that there 
was a persistent positive effect of dobesilate on quality of life 
compared to placebo (Martinez-Zapata et al. 2008), suggest-
ing a sustained therapeutic action.
Calcium  dobesilate  could  have  a  positive  effect  in  bone 
marrow edema and osteoarthritis through several mechanisms. 
Since  normal  bone  lacks  lymphatic  tissue  (Edwards  et  al. 
2008), the positive effect of calcium dobesilate on lymphatic 
circulation (Casley-Smith 1985) is unlikely to contribute. Cal-
cium dobesilate has been shown to reduce swelling and protein 
concentrations in edema by a mechanism that is independent 
of lymphatic drainage, probably by a macrophage-mediated 
effect (Casley-Smith and Casley-Smith 1985). Moreover, by 
reducing capillary permeability and albumin leakage (Tejerina 
and Ruiz 1998), the tendency for edema formation is dimin-
ished. In addition, reduction of blood viscosity and improve-
ments in blood flow (Tejerina and Ruiz 1998) may aid in 
reducing the hypoxia that occurs in subchondral bone (Kofoed 
1986, Kiaer et al. 1988), in the synovial fluid (Kofoed 1986), 
and  in  the  articular  cartilage—as  evidenced  by  increased 
hypoxia-inducible factor activity (Pfander et al. 2005). 
Alterations in growth rate or weight gain can be used as an 
objective means of monitoring the efficacy of analgesics in 
laboratory animals (Brennan et al. 2009). It does not appear 
that calcium dobesilate administration resulted in an enhanced 
analgesic effect over and above that of meloxicam, since no 
differences in weight between groups were identified.
In summary, this study indicates that calcium dobesilate has 
an effect on intramedullary pressure adjacent to an osteoar-
thritic joint. The clinical significance of this in terms of pain 
management  cannot  be  quantified  using  this  model. These 
conclusions should be seen in light of the small size of the 
study, and further investigation using larger groups is recom-
mended. Although we did not measure the presence of edema 
directly, it can be inferred from our results that calcium dobe-
silate has an effect on the presence and severity of subchondral 
bone edema in osteoarthritic joints. Use of MRI to identify 
the presence or absence of edema, or a method of quantifying 
limb use (such as force plate analysis) would be valuable in 
determining what the effects of calcium dobesilate are, and in 
defining a potential role for this compound.
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